Clinical Trial Update: A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH) [Phase 2, Phase 3]

View source ↗

Summary

AAV-101 (Dry Powder Inhaled Imatinib) trial for pulmonary arterial hypertension (Phase 2/3) funded by Aerovate Therapeutics has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• AV-101 (Dry Powder Inhaled Imatinib) (imatinib)

Snippet

Sponsor: Aerovate Therapeutics | Conditions: Pulmonary Arterial Hypertension | Phase 2, Phase 3 | Status: TERMINATED